Literature DB >> 25544873

Occult hepatitis B virus infection.

Min-Sun Kwak1, Yoon Jun Kim1.   

Abstract

Occult hepatitis B virus (HBV) infection (OBI) refers to the presence of HBV DNA in the absence of detectable hepatitis B surface antigen. Since OBI was first described in the late 1970s, there has been increasing interest in this topic. The prevalence of OBI varies according to the different endemicity of HBV infection, cohort characteristics, and sensitivity and specificity of the methods used for detection. Although the exact mechanism of OBI has not been proved, intra-hepatic persistence of viral covalently closed circular DNA under the host's strong immune suppression of HBV replication and gene expression seems to be a cause. OBI has important clinical significance in several conditions. First, OBI can be transmitted through transfusion, organ transplantation including orthotopic liver transplantation, or hemodialysis. Donor screening before blood transfusion, prophylaxis for high-risk organ transplantation recipients, and dialysis-specific infection-control programs should be considered to reduce the risk of transmission. Second, OBI may reactivate and cause acute hepatitis in immunocompromised patients or those receiving chemotherapy. Close HBV DNA monitoring and timely antiviral treatment can prevent HBV reactivation and consequent clinical deterioration. Third, OBI may contribute to the progression of hepatic fibrosis in patients with chronic liver disease including hepatitis C. Finally, OBI seems to be a risk factor for hepatocellular carcinoma by its direct proto-oncogenic effect and by indirectly causing persistent hepatic inflammation and fibrosis. However, this needs further investigation. We review published reports in the literature to gain an overview of the status of OBI and emphasize the clinical importance of OBI.

Entities:  

Keywords:  Chronic liver disease; Hepatocellular carcinoma; Occult hepatitis B virus infection; Reactivation; Transmission

Year:  2014        PMID: 25544873      PMCID: PMC4269905          DOI: 10.4254/wjh.v6.i12.860

Source DB:  PubMed          Journal:  World J Hepatol


  102 in total

1.  Lack of 'occult' hepatitis B virus infection in HIV-infected patients.

Authors:  Marina Núñez; Pilar Ríos; Mayte Pérez-Olmeda; Vincent Soriano
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

2.  What is the clinical impact of occult hepatitis B virus infection?

Authors:  Giovanni Raimondo; Teresa Pollicino; Giovanni Squadrito
Journal:  Lancet       Date:  2005 Feb 19-25       Impact factor: 79.321

Review 3.  Hepatocellular carcinoma: the point of view of the hepatitis B virus.

Authors:  Teresa Pollicino; Carlo Saitta; Giovanni Raimondo
Journal:  Carcinogenesis       Date:  2011-06-10       Impact factor: 4.944

4.  Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.

Authors:  R C Dickson; J E Everhart; J R Lake; Y Wei; E C Seaberg; R H Wiesner; R K Zetterman; T L Pruett; M B Ishitani; J H Hoofnagle
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

5.  Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

Authors:  Ming-Shen Dai; Tsu-Yi Chao; Woei-Yau Kao; Rong-Yaun Shyu; Tan-Mei Liu
Journal:  Ann Hematol       Date:  2004-08-25       Impact factor: 3.673

6.  Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection.

Authors:  Philip Kiely; Angelo R Margaritis; Clive R Seed; Hung Yang
Journal:  Transfusion       Date:  2014-03-20       Impact factor: 3.157

7.  Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study.

Authors:  Mikako Obika; Toshiyuki Shinji; Shin-Ichi Fujioka; Ryo Terada; Hiromasa Ryuko; Aye Aye Lwin; Hidenori Shiraha; Norio Koide
Journal:  Intervirology       Date:  2008-03-18       Impact factor: 1.763

Review 8.  Persistent occult hepatitis B virus infection: experimental findings and clinical implications.

Authors:  Patricia M Mulrooney-Cousins; Tomasz I Michalak
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

9.  Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C.

Authors:  Shunichi Matsuoka; Kazushige Nirei; Akinori Tamura; Hitomi Nakamura; Hiroshi Matsumura; Shuu Oshiro; Yasuo Arakawa; Hiroaki Yamagami; Naohide Tanaka; Mitsuhiko Moriyama
Journal:  Intervirology       Date:  2009-01-07       Impact factor: 1.763

Review 10.  Potential mutations associated with occult hepatitis B virus status.

Authors:  Sima Besharat; Aezam Katoonizadeh; Abdolvahab Moradi
Journal:  Hepat Mon       Date:  2014-05-03       Impact factor: 0.660

View more
  28 in total

1.  Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma.

Authors:  Shan-Shan Wu; Quan-Yuan Shan; Wen-Xuan Xie; Bin Chen; Yang Huang; Yu Guo; Xiao-Yan Xie; Ming-De Lu; Bao-Gang Peng; Ming Kuang; Shun-Li Shen; Wei Wang
Journal:  Clin Transl Oncol       Date:  2019-06-06       Impact factor: 3.405

2.  HBV/HCV Coinfection and Possible Reactivation of HBV Following DAA Use.

Authors:  Robert G Gish
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-05

Review 3.  Molecular mechanisms underlying HBsAg negativity in occult HBV infection.

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-24       Impact factor: 3.267

Review 4.  Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc Testing.

Authors:  Antonella Esposito; Chiara Sabia; Carmela Iannone; Giovanni F Nicoletti; Linda Sommese; Claudio Napoli
Journal:  Transfus Med Hemother       Date:  2017-05-05       Impact factor: 3.747

Review 5.  Optimizing antiviral agents for hepatitis B management in malignant lymphomas.

Authors:  Oluwatobi O Ozoya; Julio Chavez; Lubomir Sokol; Samir Dalia
Journal:  Ann Transl Med       Date:  2017-02

6.  Occult Hepatitis B Virus Infection among β-Thalassemia Major Patients in Ahvaz City, Iran.

Authors:  Fatemeh Amirhashchi; Azarakhsh Azaran; Seyed Saeid Seyedian; Shahram Jalilian; Bijan Keikhaei
Journal:  Am J Trop Med Hyg       Date:  2021-10-04       Impact factor: 3.707

7.  First report of occult hepatitis B infection among ART naïve HIV seropositive individuals in Maputo, Mozambique.

Authors:  Awa Abdul Carimo; Eduardo Samo Gudo; Cremildo Maueia; Nédio Mabunda; Lúcia Chambal; Adolfo Vubil; Ana Flora; Francisco Antunes; Nilesh Bhatt
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

8.  Occult HBV Infection May Be Transmitted through Close Contact and Manifest as an Overt Infection.

Authors:  Li-Ping Hu; De-Ping Liu; Qin-Yan Chen; Tim J Harrison; Xiang He; Xue-Yan Wang; Hai Li; Chao Tan; Qing-Li Yang; Kai-Wen Li; Zhong-Liao Fang
Journal:  PLoS One       Date:  2015-10-12       Impact factor: 3.240

9.  Prevalence, Risk Behaviors, and Virological Characteristics of Hepatitis B Virus Infection in a Group of Men Who Have Sex with Men in Brazil: Results from a Respondent-Driven Sampling Survey.

Authors:  Marina P Oliveira; Márcia A D Matos; Ágabo M C Silva; Carmen L R Lopes; Sheila A Teles; Marcos A Matos; Natália Spitz; Natalia M Araujo; Rosa M S Mota; Ligia R F S Kerr; Regina M B Martins
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

10.  The correlation between renal transplantation and liver carcinoma: a meta-analysis.

Authors:  Hong Yongzhi; Xu Min; Yu Bo; Chen Pin; Shi Xueqiang
Journal:  Oncotarget       Date:  2017-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.